AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	miglustat products	Page:	1 of 3
Effective Date:	7/15/2024	Last Review Date:	5/2024

Applies to:	☐ Illinois	☐ Florida	☒ New Jersey
	☒ Maryland	☒ Florida Kids	☒ Pennsylvania Kids
	☐ Michigan	☒ Virginia	☐ Kentucky PRMD

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for miglustat products under the patient's prescription drug benefit.

Description:

A. FDA-Approved Indications
   1. miglustat (generic)/Yargesa/Zavesca:
      a. Indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to allergy, hypersensitivity, or poor venous access).
   2. Opfolda:
      b. Indicated, in combination with Pombiliti, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing greater than or equal to 40 kg and who are not improving on their current enzyme replacement therapy (ERT).

B. Compendial Uses
   1. Niemann-Pick disease, type C

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

Zavesca (miglustat)
Yargesa (miglustat)
miglustat (generic)
Opfolda (miglustat)

Policy/Guideline:

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

A. Gaucher disease type 1: beta-glucocerebrosidase enzyme assay or genetic testing results supporting diagnosis.
B. Niemann-Pick disease, type C: genetic testing results showing mutations in *NPC1* or *NPC2* genes.

C. Late-onset Pompe disease:
   1. Initial requests: acid alpha-glucosidase enzyme assay or genetic testing results supporting diagnosis.
   2. Continuation requests: chart notes documenting a positive response to therapy (e.g., improvement, stabilization, or slowing of disease progression for motor function, walking capacity, respiratory function, muscle strength).

Criteria for Initial Approval:

A. Gaucher disease type 1 (miglustat (generic)/Yargesa/Zavesca only)
Authorization may be granted for treatment of Gaucher disease type 1 when ALL the following criteria are met:
1. The diagnosis of Gaucher disease was confirmed by enzyme assay demonstrating a deficiency of beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing, and
2. The member has a documented inadequate response to, intolerable adverse events with, or a clinical reason to not use enzyme replacement therapy (e.g., allergy, hypersensitivity, poor venous access).

B. Niemann-Pick disease, type C (miglustat (generic)/Yargesa/Zavesca only)
Authorization may be granted for treatment of Niemann-Pick disease, type C when the diagnosis was confirmed by genetic testing results showing mutations in *NPC1* or *NPC2* genes.

C. Late-onset Pompe disease (Opfolda only)
Authorization may be granted for treatment of late-onset Pompe disease when all the following criteria are met:
1. Member is 18 years of age or older.
2. Member weighs greater than or equal to 40 kg.
3. Diagnosis was confirmed by enzyme assay demonstrating a deficiency of acid alpha-glucosidase enzyme activity or by genetic testing.
4. The requested medication will be taken in combination with Pombiliti (cipaglucosidase alfa-atga).
5. Member is not improving on current enzyme replacement therapy (ERT) (e.g., Lumizyme, Nexviazyme).

Continuation of Therapy

A. Gaucher disease type 1 (miglustat (generic)/Yargesa/Zavesca only)

Authorization may be granted for continued treatment in members requesting reauthorization for Gaucher disease type 1 when ALL the following criteria are met:

1. The diagnosis of Gaucher disease was confirmed by enzyme assay demonstrating a deficiency of beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing.
2. Member is not experiencing an inadequate response or any intolerable adverse events from therapy.

B. Niemann-Pick disease, type C (miglustat (generic)/Yargesa/Zavesca only)

Authorization may be granted for continued treatment in members requesting reauthorization for Niemann-Pick disease, type C when ALL the following criteria are met:

1. Member meets the criteria for initial approval.
2. Member is NOT experiencing an inadequate response or any intolerable adverse events from therapy.

C. Late-onset Pompe disease (Opfolda only)

Authorization may be granted for continued treatment in members requesting reauthorization for late-onset Pompe disease who are responding to therapy (e.g., improvement, stabilization, or slowing of disease progression for motor function, walking capacity, respiratory function, or muscle strength).

Approval Duration and Quantity Restrictions:

Initial and Renewal: 12 months

Quantity Level Limit:

- Zavesca (miglustat) 100 mg capsules: 90 capsules per 30 days
- Yargesa (miglustat) 100 mg capsules: 90 capsules per 30 days
- Opfolda (miglustat) 65 mg capsules: 8 capsules per 28 days

References:

1. Zavesca [package insert]. Titusville, NJ: Actelion Pharmaceuticals US, Inc.; August 2022.
2. miglustat [package insert]. Titusville, NJ: CoTherix, Inc.; December 2022.
3. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; Updated November 24, 2023. https://online.lexi.com. Accessed December 6, 2023.
4. National Organization for Rare Disorders. (2003). *NORD guide to rare disorders.* Philadelphia: Lippincott Williams & Wilkins.
5. Opfolda [package insert]. Philadelphia, PA: Amicus Therapeutics US, LLC; September 2023
6. Yargesa [package insert]. Parsippany, NJ: Edenbridge Pharmaceuticals, LLC; January 2022.